Novo Nordisk Wegovy Cut Heart Risk by 20% in Select Trial

Novo Nordisk announced the headline results from the SELECT cardiovascular outcomes trial for Wegovy.

• Trial achieved its primary objective by demonstrating a statistically significant and superior reduction in MACE of 20% for people treated with semaglutide 2.4 mg compared to placebo
• Shares rise as much 8.5%

To view the source of this information, click here

To contact the reporter on this story:
Anton Wilen in Stockholm at awilen@bloomberg.net

To contact the editor responsible for this story:
Christopher Kingdon at ckingdon@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.